NHO Revive lands Nebraska's only prostate cancer trial site

NHO Revive in Lincoln is now Nebraska’s only site for a Johnson & Johnson Phase 3 prostate cancer trial testing pasritamig, a novel immune therapy. The study could expand treatment options for patients whose metastatic disease has continued to progress after standard therapy.

Why it matters: - The trial gives Nebraska patients access to a late-stage study of a new immune-based prostate cancer treatment without leaving the state. - Pasritamig is designed to direct T-cells at prostate cancer cells that express human kallikrein 2, or KLK2. - The approach is different from chemotherapy and hormone-based treatments. - The study focuses on patients whose disease has progressed after existing therapies, a group with limited options.

What happened: - NHO Revive became Nebraska’s only site for Johnson & Johnson’s Phase 3 KLK2-PASenger prostate cancer trial. - The site is in Lincoln. - The trial is testing pasritamig plus docetaxel versus docetaxel alone. - The sponsor is Johnson & Johnson. - NHO Revive is a joint initiative between Nebraska Hematology Oncology and Revive Research Institute.

The details: - The study is randomized and open-label. - The primary goal is to see whether the combination extends the time patients live without disease progression on imaging scans. - The trial also measures overall survival, quality of life, and additional response outcomes. - Eligible participants must have histologically confirmed metastatic prostate adenocarcinoma. - Patients must have disease that progressed despite androgen deprivation therapy and at least one prior novel hormonal therapy. - Participants must be 18 or older. - Eligible patients must have an ECOG performance status of 0 or 1. - Dr. Kailash Mosalpura, a medical oncologist at Nebraska Hematology-Oncology, said the study allows innovative treatment options to reach patients in Lincoln while advancing cancer care. - More information is available at the company's announcement.

Between the lines: - Nebraska landing a sole site for a Phase 3 trial suggests local research capacity that could matter for future oncology studies. - The focus on KLK2 highlights a more targeted strategy for advanced prostate cancer. - Because the trial is open-label, patients and clinicians will know which treatment is being given.

What's next: - NHO Revive will enroll eligible patients for the trial. - Researchers will track progression-free imaging, survival and quality-of-life outcomes. - Results will help determine whether pasritamig plus docetaxel advances to broader use if the study is successful.

The bottom line: - NHO Revive has given Nebraska a direct entry point into a pivotal test of a new immune therapy for advanced prostate cancer.